BioSpace News Archive

OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, has published a study identifying three distinct proteome subtypes that are associated with response from a cohort of non-small cell lung cancer (NSCLC) patients undergoing immunotherapy.

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the presentation of preliminary results from its ongoing Phase 1 dose escalation study evaluating COM902, Compugen’s anti-TIGIT antibody, in patients with advanced solid tumors at the 36th Annual Meeting.

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported financial results for the third quarter ended September 30, 2021.

IsoPlexis, the leader in functional single-cell proteomics, announced the appointment of two new leadership positions at the company.

Grey Wolf Therapeutics, a biotechnology company spearheading a new therapeutic approach to immuno-oncology driven by targeted neoantigen generation, today announced the presentation of promising preclinical in vivo data on the company’s first-in-class inhibitors of ERAP1 at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

Second Genome, presented preclinical data demonstrating that the Company’s CXCR3-positive allosteric modulator, SG-3-00802, can reverse resistance to anti-programmed death protein-1 (PD-1) therapy, illustrating that the microbiome directly interacts with the human immune system to enhance immunity and impact antitumor activity.

Nektar Therapeutics (Nasdaq: NKTR) today announced three data presentations for its I-O pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

CERo Therapeutics, Inc., a biopharmaceutical company pioneering the development of novel autologous engineered immune cell therapies, presented the results from preclinical in vitro studies describing the characterization of novel chimeric engulfment receptor T cells.

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today announced the presentation of data on multiple immuno-oncology programs at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting.

Bicara Therapeutics, today announced that a poster highlighting promising new preclinical data for BCA101, a bifunctional antibody designed to localize the TGF-β trap to EGFR+ tumors currently in an ongoing Phase 1/2 study, will be presented on Saturday, November 13, 2021 at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting